Logo

Grail

In Brief This Week: Meridian Bioscience, BioMérieux, Applied DNA Sciences, More

News items for the week of Dec. 12, 2022.

European Commission Outlines Intended Restorative Measures for Blocked Illumina-Grail Deal

In a Statement of Objections, the agency laid out the intended divestment and transitional measures for Illumina to unwind and dissolve the Grail acquisition.

Illumina Lowers FY 2022 Guidance as Q3 Revenues Rise 1 Percent

Illumina is taking a $3.91 billion write-off related to Grail triggered by regulatory decisions in Europe, resulting in a net loss for the quarter.

In Brief This Week: Thermo Fisher Scientific, Enzo Biochem, Codex DNA, More

News items for the week of Oct. 10, 2022.

ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform
Premium

Grail released updated data on Galleri from the PATHFINDER study, while Exact reported retrospective analysis on the performance of its test.

Sep 6, 2022

EU to Disallow Illumina's Grail Purchase

Sep 1, 2022

Illumina Says Judge Issued Favorable Decision in FTC Challenge to Grail Acquisition

Aug 12, 2022

Illumina Lowers 2022 Guidance, Braces for Fines from European Commission
Premium

Jul 19, 2022

European Commission Says Illumina 'Jumped the Gun' With Grail Deal, Threatens Fines

Jul 15, 2022

In Brief This Week: Centogene, Novacyt, T2 Biosystems, Inotiv, Oxford Nanopore, More

Jul 13, 2022

Illumina Loses Bid to Halt European Review of Grail Deal

Jul 1, 2022

In Brief This Week: Pacific Biosciences, Invitae, Grail, Mainz Biomed, Molzym, More

Jun 3, 2022

In Brief This Week: Labcorp, Grail, AnPac Bio-Medical, CDC, Agilent Technologies, More

Jun 2, 2022

Grail, AstraZeneca Partner on Companion Dx for Oncology Drugs

May 31, 2022

Grail, Veterans Affairs to Evaluate Galleri Cancer Early Detection Test

May 27, 2022

Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit

May 16, 2022

Intermountain Healthcare Rolling Out Galleri Multi-Cancer Early Detection Test in Pilot Program
Premium

May 6, 2022

Illumina Provides Updates on China Business, Grail, Upcoming Sequencing Chemistries
Premium

May 5, 2022

Illumina Q1 Revenues Grow 12 Percent

Feb 15, 2022

Point32Health to Offer Grail Cancer Early Detection Test Under Pilot Program

Feb 10, 2022

Illumina Q4 Revenues Grow 26 Percent, Full-Year 2021 Revenues Jump 40 Percent

Jan 11, 2022

Illumina Touts New Partnerships, Sequencing Technology at JP Morgan Healthcare Conference

Jan 10, 2022

Grail Partners With Premier's PINC AI to Improve Patient Access to Blood-Based Multi-Cancer Test

Nov 5, 2021

Oncology Opportunities Provide 'Pot of Gold at the End of the Double Rainbow' for Illumina
Premium

Nov 4, 2021

Illumina Q3 Revenues Grow 40 Percent

Breaking News
The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.